Xolair Label Expanded in EU – Analyst Blog
Source: http://www.zacks.com/stock/news/23961/Xolair+Label+Expanded+in+EU+-+Analyst+BlogPosted on Monday, August 24th, 2009 | In Market Commentary, Stocks to Watch
This morning, Novartis (NVS) announced that it has received approval from the European Commission (EC) for the use of Xolair (omalizumab) as an add-on therapy for severe persistent allergic asthma in children in the age group of 6 to 11 years.
The approval is positive news for the company and should expand the patient base for the drug. Asthma is a chronic lung disease which is estimated to affect about 10% of children in Europe. It is also the most common cause of school absenteeism and children often use oral corticosteroids to deal with the disease. However, despite conventional therapy, severe asthma remains uncontrolled in more than 50% of children with this condition.
Xolair is a humanized monoclonal antibody aimed at treating the underlying mechanism of allergic asthma. The product works by blocking the action of immunoglobulin E (IgE). This helps in preventing the onset of debilitating symptoms, such as shortness of breath and wheezing, in severely affected patients.
Xolair’s approval for the 6-11 age group was based partly on data from a landmark study which showed that the product reduced asthma attacks by 34% after 24 weeks of treatment. Treatment with Xolair also led to a 50% reduction in asthma attacks at one year in patients age 6 to 11 years.
The product’s overall safety and tolerability profile was consistent with that observed in the adult and adolescent population. These results were presented at the European Respiratory Society Annual Congress in 2008.
Another study showed that Xolair, when used in children age 6 to 11, significantly reduced the need for oral corticosteroids. The rate of absenteeism was also found to be lower in children taking Xolair. Xolair is already approved for use in patients aged 12 years and older with severe persistent allergic asthma.
Read the full analyst report on “NVS”
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- VIP Falls Behind Expectations - Analyst Blog - November 25th, 2009
- J. Crew Beats Zacks Estimates - Analyst Blog - November 25th, 2009
- No Change in Deere's Outlook - Analyst Blog - November 25th, 2009
- Sprint Acquires Virgin Mobile USA - Analyst Blog - November 25th, 2009
- Provenge Action Date Assigned - Analyst Blog - November 25th, 2009
Age Group, Analyst, asthma, Commission of European Communities;, Congress, Europe, european commission, lung disease, Market Commentary, Novartis, shortness of breath;, Stocks to Watch, wheezing, Xolair, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.